Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib + Paclitaxel in Inflammatory Breast Cancer
NCT00111787Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2005
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in inflammatory breast cancer (IBC), sponsored by GSK. Primary endpoint: Pathologic Complete Response Rate at 12 weeks. Started Apr 2005; status: completed.
02
Drugs
lapatinib
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT00111787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111787.